Pre-order Enquiry
Request Free Sample
Catheter-Related Bloodstream Infections (CRBSIs)- Market Insights, Epidemiology, and Market Forecast-2028
SKU ID : DEL-14679807 | Publishing Date : 01-Sep-2019 | No. of pages : 187
Detailed TOC of Catheter-Related Bloodstream Infections (CRBSIs)- Market Insights, Epidemiology, and Market Forecast-2028
1. Key Insights2. Catheter-Related Blood Stream Infection (CRBSI) Market Overview at a Glance
2.1. Total Market Share (%) Distribution of CRBSI in 2017
2.2. Total Market Share (%) Distribution of CRBSI in 2028
3. Catheter-Related Bloodstream Infection (CRBSI): Disease Background and Overview
3.1. Introduction
3.2. Difference between CLABSI and CRBSI
3.3. Causes of Catheter-Related Bloodstream Infection (CRBSI)
3.3.1. Micro-organisms
3.3.2. Intravascular Devices
3.4. Risk Factor Associated with Catheter-Related Bloodstream Infection (CRBSI)
3.5. Pathogenesis of Catheter-Related Bloodstream Infection (CRBSI)
3.6. Diagnosis of Catheter-Related Bloodstream Infection (CRBSI)
3.7. Diagnosis Guidelines Catheter-Related Bloodstream Infection (CRBSI)
3.7.1. Infectious Diseases Society of America (IDSA) Guidelines for CRBSI
3.7.2. Spanish Society of Infectious Diseases and Clinical Microbiology and (SEIMC) and the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC)
3.7.3. British Intestinal Failure Alliance (BIFA):
3.7.4. European Renal Best Practice (ERBP) Recommendations for Diagnosis of CRBSIs
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Incident Population of CRBSI in the 7MM
4.3. Total Diagnosed Incident Population of CRBSI in the 7MM
4.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the 7MM
4.5. Some KOL Insights
5. United States Epidemiology
5.1. Assumptions and Rationale
5.2. Total Incident Population of CRBSI in the United States
5.3. Total Diagnosed Incident Population of CRBSI in the United States
5.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the United States
6. EU5 Epidemiology
6.1. Germany Epidemiology
6.1.1. Assumptions and Rationale
6.1.2. Total Incident Population of CRBSI in Germany
6.1.3. Total Diagnosed Incident Population of CRBSI in Germany
6.1.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Germany
6.2. France Epidemiology
6.2.1. Assumptions and rationale
6.2.2. Total Incident Population of CRBSI in France
6.2.3. Total Diagnosed Incident Population of CRBSI in France
6.2.4. Diagnosed Incidence of CRBSI by Causative Pathogens in France
6.3. Italy Epidemiology
6.3.1. Assumptions and Rationale
6.3.2. Total Incident Population of CRBSI in Italy
6.3.3. Total Diagnosed Incident Population of CRBSI in Italy
6.3.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Italy
6.4. Spain Epidemiology
6.4.1. Assumptions and Rationale
6.4.2. Total Incident Population of CRBSI in Spain
6.4.3. Total Diagnosed Incident Population of CRBSI in Spain
6.4.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Spain
6.5. United Kingdom Epidemiology
6.5.1. Assumptions and Rationale
6.5.2. Total Incident Population of CRBSI in the United Kingdom
6.5.3. Total Diagnosed Incident Population of CRBSI in the United Kingdom
6.5.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the United Kingdom
7. Japan Epidemiology
7.1. Assumptions and Rationale
7.2. Total Incident Population of CRBSI in Japan
7.3. Total Diagnosed Incident Population of CRBSI in Japan
7.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Japan
8. Total Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Treatment of Catheter-Related Bloodstream Infection (CRBSI)
8.1.1. General
8.1.2. Short-term Central Venous or Arterial CRBSI
8.1.3. Long-term Central Venous CRBSI
8.2. Treatment Guidelines for Catheter-related bloodstream infection (CRBSI)
8.2.1. Infectious Diseases Society of America: Guidelines for the pathogen-specific treatment
8.2.2. Spanish Society of Infectious Diseases: Treatment of CRBSIs
8.3. Prevention Guidelines of Catheter-Related Bloodstream Infection (CRBSI)
8.3.1. Infectious Diseases Society of America (IDSA), Healthcare Infection Control Practices Advisory Committee (HICPAC) of the Centers for Disease Control and Prevention (CDC):
8.3.2. European Renal Best Practice (ERBP) Recommendations for Prevention of CRBSIs
9. Unmet Needs
10. Marketed Products
10.1. Neutrolin: CorMedix
10.1.1. Product Description
10.1.2. Mechanism of Action
10.1.3. Regulatory milestones
10.1.4. Clinical Development
10.1.5. Clinical Trials Information
10.1.6. Safety and Efficacy
10.1.7. Product Profile
10.2. Taurosept: Geistlich Pharma
10.2.1. Product Description
10.2.2. Mechanism of Action
10.2.3. Regulatory milestones
10.2.4. Clinical Development
10.2.5. Safety and Efficacy
10.2.6. Product Profile
10.3. Taurolock: TauroPharm GmbH
10.3.1. Product Description
10.3.2. Mechanism of Action
10.3.3. Regulatory Milestones
10.3.4. Clinical Development
10.3.5. Clinical Trials Information
10.3.6. Safety and Efficacy
10.3.7. Product Profile
10.4. IntraLock: Fresenius Medical Care
10.4.1. Product Description
10.4.2. Mechanism of Action
10.4.3. Regulatory Milestones
10.4.4. Advantages
10.4.5. Product Profile
11. Off-label Drugs
11.1. Antibacterials
11.1.1. Daptomycin
11.1.1.1. Product Description
11.1.1.2. Mechanism of Action
11.1.1.3. Generic Availability
11.1.1.4. Clinical Trials Information
11.1.2. Vancomycin
11.1.2.1. Product Description
11.1.2.2. Mechanism of Action
11.1.2.3. Generic Availability
11.1.3. Cefazolin
11.1.3.1. Product Description
11.1.3.2. Mechanism of Action
11.1.3.3. Generic Availability
11.1.4. Ampicillin
11.1.4.1. Product Description
11.1.4.2. Mechanism of Action
11.1.4.3. Generic Availability
11.1.5. Ciprofloxacin
11.1.5.1. Product Description
11.1.5.2. Mechanism of Action
11.1.5.3. Generic Availability
11.1.6. Amikacin
11.1.6.1. Product Description
11.1.6.2. Mechanism of Action
11.1.6.3. Generic Availability
11.1.7. Teicoplanin
11.1.7.1. Product Description
11.1.7.2. Mechanism of Action
11.1.7.3. Generic Availability
11.2. Antifungals
11.2.1. Fluconazole
11.2.1.1. Product Description
11.2.1.2. Mechanism of Action
11.2.1.3. Generic Availability
11.2.2. Amphotericin B
11.2.2.1. Product Description
11.2.2.2. Mechanism of Action
11.2.2.3. Generic Availability
12. Emerging Therapies
12.1. Mino-Lok: Citius Pharmaceuticals
12.1.1. Product Description
12.1.2. Other Developmental Activities
12.1.3. Clinical Development
12.1.4. Product Profile
13. CRBSI: 7MM Market Analysis
13.1. Key Findings
13.2. Market Size of CRBSI in 7MM
13.3. Market Size of CRBSI by Therapies in the 7MM
14. United States: Market Outlook
14.1. United States Market Size
14.1.1. Total Market size of CRBSI
14.1.2. Market Size of CRBSI by Therapies in the US
15. EU-5 countries: Market Outlook
15.1. Germany Market Size
15.1.1. Total Market size of CRBSI
15.1.2. Market Size of CRBSI by therapies in Germany
15.2. France Market Size
15.2.1. Total Market size of CRBSI
15.2.2. Market Size of CRBSI by therapies in France
15.3. Italy Market Size
15.3.1. Total Market size of CRBSI
15.3.2. Market Size of CRBSI by therapies in Italy
15.4. Spain Market Size
15.4.1. Total Market size of CRBSI
15.4.2. Market Size of CRBSI by therapies in Spain
15.5. United Kingdom Market Size
15.5.1. Total Market size of CRBSI
15.5.2. Market Size of CRBSI by therapies in the UK
16. Japan Market Outlook
16.1. Japan Market Size
16.1.1. Total Market size of CRBSI
16.1.2. Market Size of CRBSI by therapies in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight
List of Figures, Tables and Charts Available in Catheter-Related Bloodstream Infections (CRBSIs)- Market Insights, Epidemiology, and Market Forecast-2028
TABLE 1: TERMINOLOGY: CLABSI OR CRBSITABLE 2: VARIOUS RISK FACTORS OF CRBSI
TABLE 3: TOTAL INCIDENT POPULATION OF CRBSI IN THE 7MM (2017–2028)
TABLE 4: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE 7MM (2017–2028)
TABLE 5: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN THE 7MM (2017–2028)
TABLE 6: TOTAL INCIDENT POPULATION OF CRBSI IN THE US (2017–2028)
TABLE 7: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE US (2017–2028)
TABLE 8: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN THE US (2017–2028)
TABLE 9: TOTAL INCIDENT POPULATION OF CRBSI IN GERMANY (2017–2028)
TABLE 10: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN GERMANY (2017–2028)
TABLE 11: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN GERMANY (2017–2028)
TABLE 12: TOTAL INCIDENT POPULATION OF CRBSI IN FRANCE (2017–2028)
TABLE 13: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN FRANCE (2017–2028)
TABLE 14: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN FRANCE (2017–2028)
TABLE 15: TOTAL INCIDENT POPULATION OF CRBSI IN ITALY (2017–2028)
TABLE 16: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN ITALY (2017–2028)
TABLE 17: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN ITALY (2017–2028)
TABLE 18: TOTAL INCIDENT POPULATION OF CRBSI IN SPAIN (2017–2028)
TABLE 19: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN SPAIN (2017–2028)
TABLE 20: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN SPAIN (2017–2028)
TABLE 21: TOTAL INCIDENT POPULATION OF CRBSI IN THE UK (2017–2028)
TABLE 22: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE UK (2017–2028)
TABLE 23: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN THE UK (2017–2028)
TABLE 24: TOTAL INCIDENT POPULATION OF CRBSI IN THE JAPAN (2017–2028)
TABLE 25: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE JAPAN (2017–2028)
TABLE 26: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN JAPAN (2017–2028)
TABLE 27: THE MAIN ANTIMICROBIAL DRUG AND DOSAGE REGIMENS THAT SHOULD BE USED FOR CATHETER-RELATED INFECTIONS.
TABLE 28: NEUTROLIN (CRMD003), CLINICAL TRIAL DESCRIPTION, 2019
TABLE 29: TAUROSEPT, CLINICAL TRIAL DESCRIPTION, 2019
TABLE 30: TAUROLOCK, CLINICAL TRIAL DESCRIPTION, 2019
TABLE 31: GENERIC PRODUCTS OF DAPTOMYCIN IN THE 7MM
TABLE 32: DAPTOMYCIN, CLINICAL TRIAL DESCRIPTION, 2019
TABLE 33: GENERIC PRODUCTS OF VANCOMYCIN IN THE 7MM
TABLE 34: GENERIC PRODUCTS OF CEFAZOLIN IN THE 7MM
TABLE 35: GENERIC PRODUCTS OF AMPICILLIN IN THE 7MM
TABLE 36: GENERIC PRODUCTS OF CIPROFLOXACIN AVAILABLE IN THE 7MM
TABLE 37: GENERIC PRODUCTS OF AMIKACIN IN THE 7MM
TABLE 38: GENERIC PRODUCTS OF TEICOPLANIN IN THE 7MM
TABLE 39: GENERIC PRODUCTS OF FLUCONAZOLE IN THE 7MM
TABLE 40: GENERIC PRODUCTS OF AMPHOTERICIN B IN THE 7MM
TABLE 41: MINO-LOK, CLINICAL TRIAL DESCRIPTION, 2019
TABLE 42: MARKET SIZE OF CATHETER RELATED BLOODSTREAM INFECTION (CRBSI) IN THE 7MM IN USD MILLION (2017–2028)
TABLE 43: MARKET SIZE OF CRBSI BY THERAPIES IN THE 7MM, IN USD MILLION (2017–2028)
TABLE 44: THE US MARKET SIZE OF CRBSI IN USD MILLION (2017–2028)
TABLE 45: MARKET SIZE OF CRBSI BY THERAPIES IN THE UNITED STATES, IN USD MILLION (2017–2028)
TABLE 46: GERMANY MARKET SIZE OF CRBSI IN USD MILLION (2017–2028)
TABLE 47: MARKET SIZE OF CRBSI BY THERAPIES IN GERMANY, IN USD MILLION (2017–2028)
TABLE 48: FRANCE MARKET SIZE OF CRBSI IN USD MILLION (2017–2028)
TABLE 49: MARKET SIZE OF CRBSI BY THERAPIES IN FRANCE, IN USD MILLION (2017–2028)
TABLE 50: ITALY MARKET SIZE OF CRBSI IN USD MILLION (2017–2028)
TABLE 51: MARKET SIZE OF CRBSI BY THERAPIES IN ITALY, IN USD MILLION (2017–2028)
TABLE 52: SPAIN MARKET SIZE OF CRBSI IN USD MILLION (2017–2028)
TABLE 53: MARKET SIZE OF CRBSI BY THERAPIES IN SPAIN, IN USD MILLION (2017–2028)
TABLE 54: THE UK MARKET SIZE OF CRBSI IN USD MILLION (2017–2028)
TABLE 55: MARKET SIZE OF CRBSI BY THERAPIES IN THE UK, IN USD MILLION (2017–2028)
TABLE 56: JAPAN MARKET SIZE OF CRBSI IN USD MILLION (2017–2028)
TABLE 57: MARKET SIZE OF CRBSI BY THERAPIES IN THE JAPAN, IN USD MILLION (2017–2028)
Figure 1: Types of Central Venous and Arterial Catheter and their sites of insertion
Figure 2: Important pathogenic determinants of catheter-related infections
Figure 3: Potential sources of infection of a percutaneous intravascular device
Figure 4: Total Incident Population of CRBSI in the 7MM (2017–2028)
Figure 5: Total Diagnosed Incident Population of CRBSI in the 7MM (2017–2028)
Figure 6: Diagnosed Incidence of CRBSI by Causative Pathogens in the 7MM (2017–2028)
Figure 7: Total Incident Population of CRBSI in the US (2017–2028)
Figure 8: Total Diagnosed Incident Population of CRBSI in the US (2017–2028)
Figure 9: Diagnosed Incidence of CRBSI by Causative Pathogens in the US (2017–2028)
Figure 10: Total Incident Population of CRBSI in Germany (2017–2028)
Figure 11: Total Diagnosed Incident Population of CRBSI in Germany (2017–2028)
Figure 12: Diagnosed Incidence of CRBSI by Causative Pathogens in Germany (2017–2028)
Figure 13: Total Incident Population of CRBSI in France (2017–2028)
Figure 14: Total Diagnosed Incident Population of CRBSI in France (2017–2028)
Figure 15: Diagnosed Incidence of CRBSI by Causative Pathogens in France (2017–2028)
Figure 16: Total Incident Population of CRBSI in Italy (2017–2028)
Figure 17: Total Diagnosed Incident Population of CRBSI in Italy (2017–2028)
Figure 18: Diagnosed Incidence of CRBSI by Causative Pathogens in Italy (2017–2028)
Figure 19: Total Incident Population of CRBSI in Spain (2017–2028)
Figure 20: Total Diagnosed Incident Population of CRBSI in Spain (2017–2028)
Figure 21: Diagnosed Incidence of CRBSI by Causative Pathogens in Spain (2017–2028)
Figure 22: Total Incident Population of CRBSI in the United Kingdom (2017–2028)
Figure 23: Total Diagnosed Incident Population of CRBSI in the United Kingdom (2017–2028)
Figure 24: Diagnosed Incidence of CRBSI by Causative Pathogens in the United Kingdom (2017–2028)
Figure 25: Total Incident Population of CRBSI in Japan (2017–2028)
Figure 26: Total Diagnosed Incident Population of CRBSI in Japan (2017–2028)
Figure 27: Diagnosed Incidence of CRBSI by Causative Pathogens in Japan (2017–2028)
Figure 28: Flow chart Summarizing Approaches for Systemic Antibiotic Treatment.
Figure 29: Approach to the management of patients with short-term central venous catheter-related or arterial catheter-related bloodstream infection. CFU, colony-forming units; S. aureus, Staphylococcus aureus.
Figure 30: Approach to the treatment of a patient with a long-term central venous catheter (CVC) or a port (P)-related bloodstream infection.
Figure 31: Approach to the treatment of a patient with confirmed CRBSI.
Figure 32: Unmet Needs
Figure 33: Market Size of Catheter-Related Bloodstream Infection (CRBSI) in the 7MM in USD Million (2017–2028)
Figure 34: Market Size of CRBSI by therapies in the 7MM, in USD Million (2017–2028)
Figure 35: Market Size of CRBSI in the US, USD Millions (2017–2028)
Figure 36: Market Size of CRBSI by therapies in the United States, in USD Million (2017–2028)
Figure 37: Market Size of CRBSI in Germany, USD Millions (2017–2028)
Figure 38: Market Size of CRBSI by therapies in Germany, in USD Million (2017–2028)
Figure 39: Market Size of CRBSI in France, USD Millions (2017–2028)
Figure 40: Market Size CRBSI by therapies in France, in USD Million (2017–2028)
Figure 41: Market Size of CRBSI in Italy, USD Millions (2017–2028)
Figure 42: Market Size of CRBSI by therapies in Italy in USD Million (2017–2028)
Figure 43: Market Size of CRBSI in Spain, USD Millions (2017–2028)
Figure 44: Market Size of CRBSI by therapies in Spain in USD Million (2017–2028)
Figure 45: Market Size of CRBSI in the UK, USD Millions (2017–2028)
Figure 46: Market Size of CRBSI by therapies in the UK in USD Million (2017–2028)
Figure 47: Market Size of CRBSI in Japan, USD Millions (2017–2028)
Figure 48: Market Size of CRBSI by therapies in Japan in USD Million (2017–2028)
Figure 49: Market Drivers
Figure 50: Market Barriers
Keyplayers in Catheter-Related Bloodstream Infections (CRBSIs)- Market Insights, Epidemiology, and Market Forecast-2028
• CorMedix• Geistlich Pharma
• TauroPharm GmbH
• Fresenius Medical Care
• Citius Pharmaceuticals
Request Sample
Request Discount
